MapLight Therapeutics to Participate in Upcoming Investor Conference

MapLight Therapeutics (MPLT) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, September 14.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

MapLight Therapeutics (MPLT) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, September 14. The company’s management will present and host 1x1 investor meetings during the event.

Where available, live and archived webcasts will be posted on the Investor section of MapLight’s website under the “Events & Presentations” page at https://ir.maplightrx.com/news-events/events-presentations. MapLight is a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/09/2026 - 07:00 AM

SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:

Event: Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY)
Date: Monday, September 14^th
Format: Presenting and hosting 1x1 meetings

Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visit www.maplightrx.com.

For investor inquiries: investors@maplightrx.com

For media inquiries: media@maplightrx.com